ISTA Pharmaceuticals Announces Phase III Results For Once-Daily Topical Xibrom(TM) 0.09%

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), an ophthalmic pharmaceutical company, announced results from the Company’s recently completed Phase III clinical program of Xibrom(TM) (0.09% bromfenac sodium ophthalmic solution) QD (once-daily). The program enrolled 282 patients who underwent cataract surgery in two U.S. multi-center, randomized, double-masked, parallel-group, vehicle-controlled studies to evaluate Xibrom 0.09% dosed once daily to vehicle (placebo).

More: continued here

Filed under: Clinical Trials on December 6th, 2008